Sign in
KYTX Stock Price, Chart, Stats & News
Kyverna Therapeutics, Inc.
Save
369.60M
Market cap
–
Current P/E
–
Forward P/E
KYTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -54.90% |
ROE | -81.41% |
D/E | 0.12x |
Interest coverage ratio | -346.59x |
KYTX valuation
P/E | – |
P/S | – |
P/B | 1.58x |
P/CF | -2.39x |
P/FCF | -2.21x |
P/OCF | -2.39x |
PEG | -1.21x |
EV multiple | -2.71x |
About
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate.
Similar securities
Based on sector and market capitalization
Report issue